Tweet
Doping suspicion - J’can athlete under probe
Doping suspicion - J’can athlete under probe
BY KAYON RAYNOR Senior staff reporter raynork@jamaicaobserver.com
Wednesday, May 05, 2010
var addthis_pub="jamaicaobserver";
AN athlete from Jamaica's 12-member team to the 13th IAAF World Indoor Championships in Doha, Qatar, returned an adverse analytical finding of their "A" sample, according to highly placed Observer sources.
Adverse analytical finding refers to the "presence of a prohibited substance or its metabolites or markers (including elevated quantities of endogenous substances) or evidence of the use of a prohibited method", as outlined in the 2010-2011 IAAF's Competition Rules book.
It is understood that the athlete, who cannot be named at this stage, has requested that the "B" sample be tested.
The Jamaica Amateur Athletics Association (JAAA) would not confirm whether they had been notified of the finding from the testing of any of the nation's athletes.
"I don't know if any of the doctors have heard anything. But no, I haven't heard anything," said president of the JAAA Howard Aris when contacted by the Observer on Monday.
But his response is not surprising.
Rule 37.11 of the 2010-2011 IAAF Competition Rules book stipulates that: "Persons connected with Doping Control shall take all reasonable steps to maintain confidentiality until the "B" sample analysis has been concluded (or until any follow-up investigation to the "B" sample analysis as maybe required by the Prohibited List under rule 37.9 has been concluded), or until the "B" sample analysis is waived by the athlete."
The book further notes that: "The identity of athletes or other persons who are alleged to have committed anti-doping rule violations may be publicly disclosed only after notice has been provided to the athlete or other person in accordance with Rule 37.4 or 37.10 and, in normal circumstances, no earlier than the imposition of a Provisional Suspension in accordance with Rule 38.2 or Rule 38.3."
Meanwhile, it is unclear whether the result of that "B" sample has been returned from the WADA-accredited laboratory.
In accordance with the IAAF Anti-Doping process, after the "B" sample is returned and any follow-up investigation is carried out, the athlete in question shall be afforded an opportunity, either directly or through his National Federation, within a time limit set by the IAAF to provide an explanation in response to the anti-doping rule violation asserted.
Subsequent to receiving the result of the "B" sample, the athlete has the right to request a hearing.
"If a hearing is requested by an athlete, it shall be convened without delay and the hearing held within three months of the date of notification of the athlete's request to the Member," states Rule 38.9 of the 2010-2011 IAAF Competition Rules book.
Meanwhile, second vice-president of the JAAA, Dr Warren Blake, who served as team leader and doctor for the team to Doha, told the Observer he was unaware of any adverse analytical finding concerning any Jamaican athlete coming out of the meet.
"We haven't received anything from the IAAF, but if anything happens, we'll get information in due course," he said on Monday. "So far, no information."
Dr Herb Elliot, who serves on both the IAAF's Medical and Anti-doping Commission as well as the Jamaica Anti-doping Commission, also denied knowledge of the latest adverse analytical finding by the Jamaican athlete.
Jamaica won the gold medal in the women's 60-metre dash and a bronze in the women's 4x400m relay at the March 12-14 meet.
News of this latest drug infringement comes on the heels of last month's confirmation that reigning Olympic and World Championship 400m gold medallist American LaShawn Merritt tested positive for the banned substance DHEA.
Last year, Jamaicans Lansford Spence, Marvin Anderson, Yohan Blake, Allodin Fothergill and Sheri-Ann Brooks returned adverse analytical findings for the banned substance 4-Methyl-2-Hexanamine at the National Trials, ahead of the Berlin World Championships.
In January, Brooks was cleared of any wrongdoing by the IAAF, while the other four served three-month suspensions.
In 2008, the Observer also broke the news that sprinter Julien Dunkley had tested positive for the banned drug Boldenone.
Dunkley, who denied using the banned drug, was removed from Jamaica's team to the Beijing Olympics and was later handed a two-year ban by the IAAF.
Dunkley's positive test was the second to have been detected by local authorities since 2004. Sprinter Steve Mullings, who won the 200 metres at the 2004 Olympic Trials, was banned for two years after testing positive for testosterone.
Other Jamaicans to have tested positive for banned substances include sprinters Merlene Ottey (Nandrolone); Patrick Jarrett (Stanozolol); shot putter Dorian Scott (marijuana) and long/triple jumper Suzette Lee (Salbutamol, which is used for the treatment of asthma, chronic bronchitis and other breathing disorders).
Jarrett was suspended for two years, while Ottey escaped a ban as her "B" sample returned negative. Scott and Lee both received public warnings.
BY KAYON RAYNOR Senior staff reporter raynork@jamaicaobserver.com
Wednesday, May 05, 2010
var addthis_pub="jamaicaobserver";
AN athlete from Jamaica's 12-member team to the 13th IAAF World Indoor Championships in Doha, Qatar, returned an adverse analytical finding of their "A" sample, according to highly placed Observer sources.
Adverse analytical finding refers to the "presence of a prohibited substance or its metabolites or markers (including elevated quantities of endogenous substances) or evidence of the use of a prohibited method", as outlined in the 2010-2011 IAAF's Competition Rules book.
It is understood that the athlete, who cannot be named at this stage, has requested that the "B" sample be tested.
The Jamaica Amateur Athletics Association (JAAA) would not confirm whether they had been notified of the finding from the testing of any of the nation's athletes.
"I don't know if any of the doctors have heard anything. But no, I haven't heard anything," said president of the JAAA Howard Aris when contacted by the Observer on Monday.
But his response is not surprising.
Rule 37.11 of the 2010-2011 IAAF Competition Rules book stipulates that: "Persons connected with Doping Control shall take all reasonable steps to maintain confidentiality until the "B" sample analysis has been concluded (or until any follow-up investigation to the "B" sample analysis as maybe required by the Prohibited List under rule 37.9 has been concluded), or until the "B" sample analysis is waived by the athlete."
The book further notes that: "The identity of athletes or other persons who are alleged to have committed anti-doping rule violations may be publicly disclosed only after notice has been provided to the athlete or other person in accordance with Rule 37.4 or 37.10 and, in normal circumstances, no earlier than the imposition of a Provisional Suspension in accordance with Rule 38.2 or Rule 38.3."
Meanwhile, it is unclear whether the result of that "B" sample has been returned from the WADA-accredited laboratory.
In accordance with the IAAF Anti-Doping process, after the "B" sample is returned and any follow-up investigation is carried out, the athlete in question shall be afforded an opportunity, either directly or through his National Federation, within a time limit set by the IAAF to provide an explanation in response to the anti-doping rule violation asserted.
Subsequent to receiving the result of the "B" sample, the athlete has the right to request a hearing.
"If a hearing is requested by an athlete, it shall be convened without delay and the hearing held within three months of the date of notification of the athlete's request to the Member," states Rule 38.9 of the 2010-2011 IAAF Competition Rules book.
Meanwhile, second vice-president of the JAAA, Dr Warren Blake, who served as team leader and doctor for the team to Doha, told the Observer he was unaware of any adverse analytical finding concerning any Jamaican athlete coming out of the meet.
"We haven't received anything from the IAAF, but if anything happens, we'll get information in due course," he said on Monday. "So far, no information."
Dr Herb Elliot, who serves on both the IAAF's Medical and Anti-doping Commission as well as the Jamaica Anti-doping Commission, also denied knowledge of the latest adverse analytical finding by the Jamaican athlete.
Jamaica won the gold medal in the women's 60-metre dash and a bronze in the women's 4x400m relay at the March 12-14 meet.
News of this latest drug infringement comes on the heels of last month's confirmation that reigning Olympic and World Championship 400m gold medallist American LaShawn Merritt tested positive for the banned substance DHEA.
Last year, Jamaicans Lansford Spence, Marvin Anderson, Yohan Blake, Allodin Fothergill and Sheri-Ann Brooks returned adverse analytical findings for the banned substance 4-Methyl-2-Hexanamine at the National Trials, ahead of the Berlin World Championships.
In January, Brooks was cleared of any wrongdoing by the IAAF, while the other four served three-month suspensions.
In 2008, the Observer also broke the news that sprinter Julien Dunkley had tested positive for the banned drug Boldenone.
Dunkley, who denied using the banned drug, was removed from Jamaica's team to the Beijing Olympics and was later handed a two-year ban by the IAAF.
Dunkley's positive test was the second to have been detected by local authorities since 2004. Sprinter Steve Mullings, who won the 200 metres at the 2004 Olympic Trials, was banned for two years after testing positive for testosterone.
Other Jamaicans to have tested positive for banned substances include sprinters Merlene Ottey (Nandrolone); Patrick Jarrett (Stanozolol); shot putter Dorian Scott (marijuana) and long/triple jumper Suzette Lee (Salbutamol, which is used for the treatment of asthma, chronic bronchitis and other breathing disorders).
Jarrett was suspended for two years, while Ottey escaped a ban as her "B" sample returned negative. Scott and Lee both received public warnings.
.
Comment